BACKGROUND: The impact of virologic response on hepatic function has not been previously defined. AIM: To determine the relationships of quantitative liver function tests (QLFTs) with virological responses to peginterferon (PEG) +/- ribavirin (RBV) in patients with chronic hepatitis C and to use serial QLFTs to define the spectrum of hepatic improvement after sustained virological response (SVR). METHODS:Participants (n = 232) were enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial, had failed prior therapy, had bridging fibrosis or cirrhosis and were retreated with PEG/RBV. All 232 patients had baseline QLFTs; 24 patients with SVR and 68 nonresponders had serial QLFTs. Lidocaine, [24-(13)C]cholate, galactose and (99m)Tc-sulfur colloid were administered intravenously; [2,2,4,2-(2)H]cholate, [1-(13)C]methionine, caffeine and antipyrine were administered orally. Clearances (Cl), breath (13)CO(2), monoethylglycylxylidide (MEGX), perfused hepatic mass (PHM) and liver volume were measured. RESULTS:Rates of SVR were 18-26% in patients with good function by QLFTs, but < or =6% in patients with poor function. Hepatic metabolism, measured by caffeine k(elim) (P = 0.02), antipyrine k(elim) (P = 0.05) and antipyrine Cl (P = 0.02) and the portal circulation, measured by cholate Cl(oral) (P = 0.0002) and cholate shunt (P = 0.0003) and PHM (P = 0.03) improved after SVR. CONCLUSION: Hepatic dysfunction impairs the virological response to PEG/RBV. SVR improves hepatic metabolism, the portal circulation and PHM.
RCT Entities:
BACKGROUND: The impact of virologic response on hepatic function has not been previously defined. AIM: To determine the relationships of quantitative liver function tests (QLFTs) with virological responses to peginterferon (PEG) +/- ribavirin (RBV) in patients with chronic hepatitis C and to use serial QLFTs to define the spectrum of hepatic improvement after sustained virological response (SVR). METHODS:Participants (n = 232) were enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial, had failed prior therapy, had bridging fibrosis or cirrhosis and were retreated with PEG/RBV. All 232 patients had baseline QLFTs; 24 patients with SVR and 68 nonresponders had serial QLFTs. Lidocaine, [24-(13)C]cholate, galactose and (99m)Tc-sulfur colloid were administered intravenously; [2,2,4,2-(2)H]cholate, [1-(13)C]methionine, caffeine and antipyrine were administered orally. Clearances (Cl), breath (13)CO(2), monoethylglycylxylidide (MEGX), perfused hepatic mass (PHM) and liver volume were measured. RESULTS: Rates of SVR were 18-26% in patients with good function by QLFTs, but < or =6% in patients with poor function. Hepatic metabolism, measured by caffeine k(elim) (P = 0.02), antipyrine k(elim) (P = 0.05) and antipyrine Cl (P = 0.02) and the portal circulation, measured by cholate Cl(oral) (P = 0.0002) and cholate shunt (P = 0.0003) and PHM (P = 0.03) improved after SVR. CONCLUSION:Hepatic dysfunction impairs the virological response to PEG/RBV. SVR improves hepatic metabolism, the portal circulation and PHM.
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: L B Seeff; F B Hollinger; H J Alter; E C Wright; C M Cain; Z J Buskell; K G Ishak; F L Iber; D Toro; A Samanta; R L Koretz; R P Perrillo; Z D Goodman; R G Knodell; G Gitnick; T R Morgan; E R Schiff; S Lasky; C Stevens; R Z Vlahcevic; E Weinshel; T Tanwandee; H J Lin; L Barbosa Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245
Authors: G T Everson; M L Shiffman; T R Morgan; J C Hoefs; R K Sterling; D A Wagner; C C Kulig; T M Curto; E C Wright Journal: Aliment Pharmacol Ther Date: 2008-02-07 Impact factor: 8.171
Authors: Gregory T Everson; Mitchell L Shiffman; John C Hoefs; Timothy R Morgan; Richard K Sterling; David A Wagner; Shannon Lauriski; Teresa M Curto; Anne Stoddard; Elizabeth C Wright Journal: Hepatology Date: 2012-03-01 Impact factor: 17.425
Authors: Gregory T Everson; John C Hoefs; Claus U Niemann; Kim M Olthoff; Robert Dupuis; Shannon Lauriski; Andrea Herman; Norah Milne; Brenda W Gillespie; Nathan P Goodrich; James E Everhart Journal: Liver Transpl Date: 2013-03 Impact factor: 5.799
Authors: Jordan J Feld; Apurva A Modi; Ramy El-Diwany; Yaron Rotman; Emmanuel Thomas; Golo Ahlenstiel; Rachel Titerence; Christopher Koh; Vera Cherepanov; Theo Heller; Marc G Ghany; Yoon Park; Jay H Hoofnagle; T Jake Liang Journal: Gastroenterology Date: 2010-09-17 Impact factor: 22.682
Authors: Kim M Olthoff; Abigail R Smith; Michael Abecassis; Talia Baker; Jean C Emond; Carl L Berg; Charlotte A Beil; James R Burton; Robert A Fisher; Chris E Freise; Brenda W Gillespie; David R Grant; Abhinav Humar; Igal Kam; Robert M Merion; Elizabeth A Pomfret; Benjamin Samstein; Abraham Shaked Journal: Ann Surg Date: 2015-09 Impact factor: 12.969
Authors: Jeremiah Bowers; Emma Hughes; Nicholas Skill; Mary Maluccio; Daniel Raftery Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2014-03-02 Impact factor: 3.205
Authors: Kristin K Snow; Margaret C Bell; Anne M Stoddard; Teresa M Curto; Elizabeth C Wright; Jules L Dienstag Journal: Trials Date: 2014-05-07 Impact factor: 2.279